All Articles
Minimal residual disease assessments are increasingly being used in the clinical trial setting. Read More ›
Updated analysis of IKEMA showed improved responses with isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Read More ›
Ciltacabtagene autoleucel has been shown to have compelling survival benefit, and a new study shows improved health-related quality of life in patients with triple-class exposed multiple myeloma. Read More ›
Final analysis of ICARIA-MM supports isatuximab plus pomalidomide and dexamethasone as standard of care in patients with relapsed/refractory multiple myeloma. Read More ›
Continuing medical education and nursing continuing professional development–approved activities can improve clinicians’ knowledge of the fast-emerging treatment landscape in multiple myeloma. Read More ›
Daratumumab plus lenalidomide and dexamethasone showed deep clinical responses in patients who continued treatment for ≥18 months. Read More ›
Dr Tycel Phillips debates the importance of having more effective and better tolerated treatments for patients who present with recurrent or treatment-refractory follicular lymphoma (FL). Often, these patients have undergone more than 1 or 2 previous lines of therapy and cannot tolerate all types of therapies within the gamut of potential choices. In such patients, it is desirable to have flexibility in the choice of a therapy regimen, for example, one that is chemotherapy-free. Ms Peg Rummel commented that oncology nurses and nurse navigators are paramount in educating the patients and their caregivers around all aspects of therapy, and help alleviate psychological stress, anxiety, and fear of the unknown by explaining to patients with relapsed or refractory FL the various paths along their therapeutic journey. Read More ›
Dr Andrew Zelenetz examines the various criteria used in individual patients with relapsed or treatment-refractory follicular lymphoma and how they help determine the trigger for and timing of initiating antitumor therapies. Dr Tycel Phillips expands on how applying such criteria may best guide the oncologist to choose specific treatment options, such as certain classes of currently available (FDA-approved) drugs in monotherapy or in combination, especially in a community-based clinical setting. Read More ›
Drs Andrew Zelenetz and Tycel Phillips explore the role B-cell signaling plays in the development and progression of follicular lymphoma (FL) and explain how this underlies the pathophysiology of FL. These biological mechanisms underlie the way that FL differs from other B-cell malignancies, and, in many ways, help select candidate molecular targets for the development of novel agents for the management of FL. Read More ›
Dr Tycel Phillips provides an overview of the most common presenting clinical symptoms at the time of initial presentation of patients with follicular lymphoma (FL). Dr Andrew Zelenetz expands on this discussion by delineating the wide range of possible clinical manifestations, from complete lack of symptoms—whereby FL is found incidentally, for example during routine imaging—to severe and debilitating B-symptoms. Ms Peg Rummel emphasizes the role of nurses and nurse navigators, as members of a multidisciplinary clinical team, in directing patients to the appropriate HCP, as well as educate them on the value of tumor tissue biopsy for a definitive diagnosis of FL, which is a prerequisite to the delivery of appropriate therapy. Read More ›